FDA OKs First 'Biosimilar' Drug to Fight Cancer

FDA OKs First 'Biosimilar' Drug to Fight Cancer

The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration.

Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of adults with certain colon, lung, brain, kidney and cervical cancers.

A biosimilar is a biological product that is approved because it is highly similar to an already-approved biologic drug and has no significant differences in safety and effectiveness from the first product, the FDA explained.

"Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower health care costs and increase access to important therapies," FDA Commissioner Dr. Scott Gottlieb said in an agency news release.

Mvasi is marketed by Amgen, Inc., headquartered in Thousand Oaks, Calif.

Like Avastin, the labeling for Mvasi has a boxed warning about an increased risk of: holes in the stomach and intestines; surgery and wound healing complications; and severe or fatal pulmonary, gastrointestinal, central nervous system and vaginal bleeding.

Common side effects of Mvasi include nosebleeds, headache, high blood pressure, inflammation of the nasal cavity, high levels of protein in the urine, taste alteration, dry skin, rectal bleeding, excessive tear production, back pain and skin irritation, according to the FDA.

Women who are pregnant should not take Mvasi because it may cause harm to a developing fetus.

More information

The U.S. Food and Drug Administration has more on biosimilars.


Copyright © 2013-2017 HealthDay. All rights reserved.

Mental Health Does Not Come With A Manual, It Comes With Friends & Family Support That Never Gives Up!
Join now

Related Content

What If Your Anxiety & Depression Is Really A Sign Of ADHD?
What If Your Anxiety & Depression Is Really A Sign Of ADHD?

More often than not, when a person over the age of 10 is diagnosed with attentio...

Read more
New Patent By OxyContin Maker May Treat Pain But Comes With Addictive Potential
New Patent By OxyContin Maker May Treat Pain But Comes With Addictive Potential

Purdue Pharma, the maker of OxyContin, has received a patent designed to treat o...

Read more
Why Are Transgenders Experiencing More Mental Health Issues Than The General Public?
Why Are Transgenders Experiencing More Mental Health Issues Than The General Public?

Individuals who identify as transgender tend to experience higher rates of menta...

Read more
New Research In Schizophrenia Shows That A Video Game Can Aid In Preventing Hallucinations
New Research In Schizophrenia Shows That A Video Game Can Aid In Preventing Hallucinations

People with schizophrenia can be trained by playing a video game to control the ...

Read more
I was 12 When I Survived 9-11 But My Peers & I Are Only Now Realizing Our PTSD
I was 12 When I Survived 9-11 But My Peers & I Are Only Now Realizing Our PTSD

As the Twin Towers burned and eventually collapsed on 9/11, I was running from m...

Read more
How Running Helped These Everyday People Beat OCD, Depression & Anxiety
How Running Helped These Everyday People Beat OCD, Depression & Anxiety

When documentary photographer Martin Eberlen was diagnosed with ADHD in his earl...

Read more